Celcuity Inc. has unveiled a corporate presentation highlighting its developments in targeting cancers involving the PI3K/AKT/mTOR $(PAM)$ pathway, a significant area in oncology. The company focuses on leveraging gedatolisib, a differentiated PAM inhibitor with a potent and well-tolerated mechanism of action, showing promising data in both first-line and second-line patients with HR+/HER2- advanced breast cancer. The presentation also outlines plans for Phase 3 studies and discusses the potential for developing treatments for prostate cancer due to parallels with breast cancer. Celcuity is strategically positioned to advance multiple indications in breast and prostate cancer, supported by substantial cash reserves. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.